Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.
The Los Angeles-based company said in a regulatory filing on Wednesday it expects net proceeds of $5.6 million, which it plans to use to fund clinical development of its lead product candidates. Proceeds will also be used for paying outstanding accounts payable, working capital and general corporate purposes.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Already a subscriber?
Log In
